tradingkey.logo
tradingkey.logo
検索

Klotho Neurosciences Ord Shs

GRML
ウォッチリストに追加
3.570USD
-0.340-8.70%
終値 11-05 16:00(ET)
42.95M時価総額
損失額直近12ヶ月PER
時間外取引 18:18 (ET)3.510USD-0.075-2.09%

Klotho Neurosciences Ord Shsについて 企業名

Klotho Neurosciences, Inc. operates with two divisions: Natural Resources and Cell and Gene Therapy. The Natural Resources division is focused on the exploration and development of the Skaergaard Project in Southeast Greenland, which is undeveloped palladium, gold, and platinum deposits. The Skaergaard Project is located in Southeast Greenland, which is an undeveloped palladium, gold, and platinum deposit. It operates three Mineral Exploration Licenses (MEL): MEL 2007-01, MEL 2012-25, and MEL 2021-10. The Cell and Gene Therapy division includes the Company's KLTO-202 primary indication for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease). It is engaged in developing and providing new therapies to alleviate and/or reverse the progression of neurodegenerative diseases through the use of cell and gene therapy. It is also focusing on developing therapeutic agents for the treatments for Alzheimer's and Parkinson's disease.

Klotho Neurosciences Ord Shs プロフィール

企業コード- -
会社名- -
上場日- -
最高経営責任者「CEO」- -
従業員数- -
証券種類- -
決算期末- -
本社所在地- -
都市- -
証券取引所- -
国- -
郵便番号- -
電話番号- -
ウェブサイト- -
企業コード- -
上場日- -
最高経営責任者「CEO」- -

Klotho Neurosciences Ord Shsの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Joseph Sinkule
Dr. Joseph Sinkule
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
126.93K
--
Dr. Joseph Sinkule
Dr. Joseph Sinkule
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
126.93K
--
Dr. Joseph Sinkule
Dr. Joseph Sinkule
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
126.93K
--
Dr. Samuel M. Zentman, Ph.D.
Dr. Samuel M. Zentman, Ph.D.
Independent Director
Independent Director
21.73K
--
Dr. Samuel M. Zentman, Ph.D.
Dr. Samuel M. Zentman, Ph.D.
Independent Director
Independent Director
21.73K
--
Dr. Samuel M. Zentman, Ph.D.
Dr. Samuel M. Zentman, Ph.D.
Independent Director
Independent Director
21.73K
--
Mr. Peter J. Moriarty
Mr. Peter J. Moriarty
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Jeffrey (Jeff) LeBlanc
Mr. Jeffrey (Jeff) LeBlanc
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jason D. Sawyer
Mr. Jason D. Sawyer
Director
Director
--
--
Mr. Jason Hawkins
Mr. Jason Hawkins
Director
Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Joseph Sinkule
Dr. Joseph Sinkule
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
126.93K
--
Dr. Joseph Sinkule
Dr. Joseph Sinkule
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
126.93K
--
Dr. Joseph Sinkule
Dr. Joseph Sinkule
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
126.93K
--
Dr. Samuel M. Zentman, Ph.D.
Dr. Samuel M. Zentman, Ph.D.
Independent Director
Independent Director
21.73K
--
Dr. Samuel M. Zentman, Ph.D.
Dr. Samuel M. Zentman, Ph.D.
Independent Director
Independent Director
21.73K
--
Dr. Samuel M. Zentman, Ph.D.
Dr. Samuel M. Zentman, Ph.D.
Independent Director
Independent Director
21.73K
--

よくある質問

Klotho Neurosciences Ord Shsの上位5名の株主は誰ですか?

Klotho Neurosciences Ord Shsの上位5名の株主は以下のとおりです。Dr. Joseph Sinkule
tradingkey.logo
リスク告知:当社ウェブサイト及びモバイルアプリは特定の投資商品に関する一般的な情報のみを提供しており、Finsightsは金融アドバイスや投資商品の推奨を行うものではありません。本情報の提供をもってFinsightsが投資助言を行っていると解釈されることはありません。
投資商品には元本割れを含む重大なリスクが伴い、全ての投資家に適するものではありません。なお、過去の運用実績は将来の成果を保証するものではありません。
Finsightsは、第三者広告主または提携先が当社ウェブサイト・モバイルアプリ上に広告を掲載することを許可する場合があり、これら広告主から広告への反応に基づく報酬を受けることがあります。
© 著作権: FINSIGHTS MEDIA PTE. LTD. 無断複写・転載を禁じます。